Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors

1. A compound of formula I

wherein:

X and Y are independently —C(R3)(R4)-, —(C═O)—, or —(C═S), provided that at least one of X and Y is —(C═O)—or —(C═S)—, and X and Y cannot both simultaneously be —(C═O)—or —(C═S)—, or

X and Y together are C(R3)=C(R3);

R is —(C═O )—NR1aR2a, —(C═O)—O—R1b, (C 1 -C 5 )-haloalkyl, (CR5R6) m -O(R7), (C 1 -C 3 )-alkyloxy-(C 1 -C 3 )-alkylene, aryl, heterocycle, (C 1 -C 4 )-alkylene-aryl, (C 1 -C 4 )-alkylene-heteroaryl, or (C 1 -C 4 )-alkylene-(C 5 -C 12 )-cycloalkyl, wherein the cycloalkyl, aryl, heterocycle or heteroaryl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy—(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, (C 0 -C 8 ) -alkylene-heteroaryl, N(R5)(R6), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), N(R5)CO(R6), N(R5)SO 2 (R6), CO(R5), (CR5R6) m -O(R7), O—CO—N(R5)(R6), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 ) -alkylene-CO —OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R5)(R6), wherein the aryl or heteroaryl may in turn be substituted one or more times by

F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R8)(R9), SO 2 —CH 3 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R8)(R9), N(R8)CO(R9), N(R8)SO 2 (R9), CO(R8), (CR8R9) m ″-O(R10), O—CO—N(R8)(R9), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R8)(R9); or

R and X when X is —C(R3)(R4)-, together with the nitrogen atom to which they are attached form a monocyclic, saturated or partly unsaturated 4- to 7-membered ring system or a bicyclic saturated or partly unsaturated 8- to 14-membered ring system whose individual members of the ring systems may be replaced by one to three atoms or atomic groups selected from —CHR11-, —CR11R12-, —(C═R11)-, =C(R11)-, —NR11-, —C(=O)-, —O—, —S—, —SO—, and —SO 2 -, provided that two units from the series —O—, —S—, —SO—, and —SO 2 — may not be adjacent;

m, m′ and m″ are independently 0, 1, 2, 3, 4, 5, or 6;

R5, R6, R7, R8, R9 and R10 are independently hydrogen or (C 1 -C 8 )-alkyl;

R11 and R12 are independently hydrogen, (C 1 -C 6 )-alkyl, aryl, (C 3 -C 12 )-cycloalkyl, (C 1 -C 4 )-alkylene-aryl, or (C 1 -C 3 )-alkylene-(C 3 -C 12 )-cycloalkyl, wherein the aryl or cycloalkyl may be substituted by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R13)(R14), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R13)(R14), N(R13)CO(R14), N(R13)SO 2 (R14), CO(R13), (CR13R14) n -O(R15), O—CO—N(R13)(R14), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R13)(R14);

n is 0, 1, 2, 3, 4, 5, or 6;

R13, R14 and R15 are independently hydrogen or (C 1 -C 8 )-alkyl;

R1, R1a and R1b are independently (C 5 -C 16 )-alkyl, CH 2 -aryl, (C 1 -C 2 )-alkylene-heteroaryl, or CH 2 —(C 5 -C 12 )-cycloalkyl, wherein the aryl, heteroaryl or cycloalkyl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, (C 0 -C 8 )-alkylene-heteroaryl, N(R16)(R17), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, CCO—(C 1 -C 6 )-alkyl, CON(R16)(R17), N(R16)CO(R17), N(R16)SO 2 (R17), CO(R16), (CR16R17) 0 -O(R18), O—CO—N(R16)(R17), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R16)(R17), wherein the aryl or heteroaryl in turn may be substituted one or more times by

F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R19)(R20), SO 2 —CH 3 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R19)(R20), N(R19)CO(R20), N(R19)SO 2 (R20), CO(R19), (CR19R20) 0 -O(R21), O—CO—N(R19)(R20), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R19)(R20);

o and o′ are independently 0, 1, 2, 3, 4, 5, or 6;

R16, R17, R18, R19, R20 and R21 are independently hydrogen or (C 1 -C 8 )-alkyl; or

R1, Rla and Rlb may independently be a radical of formula Ia

wherein:

W is —C(R28)(R29)-, —C(R28)(R29)—C(R28a)(R29a)-, or —C(R28)(R29)—O—;

R22, R23, R24, R25, R26, R27, R28, R29, R28a, R29a are independently hydrogen, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , SF 5 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkenyl, (C 2 -C 6 )-alkynyl, N(R30)(R31), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R30)(R31), N(R30)CO(R31), N(R30)SO 2 (R31), CO(R30), (CR30R31) p -O(R32), O—CO—N(R30)(R31), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R30)(R31); or

R22 and R28 or R23 and R29 together with the carbon atoms to which they are attached form a monocyclic, 5 or 6 membered saturated, partly unsaturated or aromatic ring system whose individual members may be replaced by —CHR33-, —CR33R34-, or =(C—R33)-; or R24 and R26, or R25 and R27 together with the carbon atoms to which they are attached form a monocyclic, 5 or 6 membered saturated, partly unsaturated or an aromatic ring system whose individual members may be replaced by —CHR33-, —CR33R34-, or =(C—R33)-;

p is 0, 1, 2, 3, 4, 5, or 6;

R30, R31 and R32 are independently hydrogen or (C 1 -C 6 )-alkyl;

R33 and R34 are independently F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , SF 5 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R35)(R36), SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R35)(R36), N(R35)CO(R36), N(R35)SO 2 (R36), CO(R35), (CR35R36) q -O(R37), O—CO—N(R35)(R36), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R35)(R36);

q is 0, 1, 2, 3, 4, 5, or 6;

R35, R36 and R37 are independently hydrogen or (C 1 -C 6 )-alkyl;

R2 and R2a are independently hydrogen or (C 1 -C 8 -alkyl; and

R3 and R4 are independently hydrogen, (C 1 -C 6 )-alkyl, or benzyl;

or a tautomeric form or a physiologically tolerated salt thereof;

provided that R1 is not pentyl, CH 2 -phenyl, —CH 2 -(2-Cl-phenyl), cyclohexyl, or -(2-methylcyclohexyl) when X is CH 2 , Y is CO, R is methyl and R2 is H.

2. The compound according to claim 1 , wherein R2 is hydrogen, or a tautomeric form or a physiologically tolerated salt thereof.

3. The compound according to claim 1 , wherein

Y is —(C═O)—; and

X is —C(R3)(R4)-;

or

X is —(C═O)—; and

Y is —C(R3(R4)-;

R is —(C═O)—NR1aR2a, —(C═O)—O—R1b, (C 1 -C 3 )-haloalkyl, (CR5R6) m -O(R7), phenyl, heterocycle, (C 1 -C 4 )-alkylene-phenyl, (C 1 -C 4 )-alkylene-heteroaryl, or (C 1 -C 4 )-alkylene-(C 5 -C 12 )-cycloalkyl, wherein the cycloalkyl, phenyl, heterocycle or heteroaryl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-aryl, O—(C 0 -C 8 )-alkylene-aryl, S-aryl, (C 0 -C 8 )-alkylene-heteroaryl, N(R5)(R6), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), N(R5)CO(R6), N(R5)SO 2 (R6), CO(R5), (CR5R6) m -O(R7), O—CO—N(R5)(R6), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R5)(R6), where the aryl or heteroaryl may in turn be substituted one or more times by

F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R8)(R9), SO 2 —CH 3 , SF 5 , COOH, CCO—(C 1 -C 6 )-alkyl, CON(R8)(R9), N(R8)CO(R9), N(R8)SO 2 (R9), CO(R8), (CR8R9) m -O(R10), O—CO—N(R8)(R9), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene -CO—N(R8)(R9); or

R and X when X is —C(R3)(R4)-, together with the nitrogen atom to which they are attached form a monocyclic, saturated 5- to 7-membered ring system or a bicyclic partly unsaturated 8- to 14 membered ring system whose individual members may be replaced by one to three atoms or atomic groups selected from —CHR11-, —CR11R12-, —(C═R11)-, —NR11-, —C(═O)—, and —O—, provided that two units of —O—may not be adjacent;

R11 and R12 are independently hydrogen, (C 1 -C 6 )-alkyl, phenyl, (C 3 -C 12 )-cycloalkyl, (C 1 -C 4 )-alkylene-phenyl, or (C 1 -C 3 )-alkylene—(C 3 -C 12 )-cycloalkyl, wherein the phenyl or cycloalkyl may be substituted by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R13)(R14), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, CCO—(C 1 -C 6 )-alkyl, CON(R13)(R14), N(R13)CO(R14), N(R13)SO 2 (R14), CO(R13), (CR13R14) n -O(R15), O—CO—N(R13)(R14), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R13)(R14); and

R1, R1a and R1b are independently (C 5 -C 12 )-alkyl, —CH 2 -phenyl, (C 1 -C 2 )-alkylene-heteroaryl, —CH 2 —(C 5 -C 12 )-cycloalkyl, or (C 5 -C 6 )-cycloalkyl, wherein the phenyl, heteroaryl or cycloalkyl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, (C 0 -C 8 )-alkylene-phenyl, O—(C 0 -C 8 )-alkylene-phenyl, S-phenyl, (C 0 -C 8 )-alkylene-heteroaryl, N(R16)(R17), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, CCO—(C 1 -C 6 )-alkyl, CON(R16)(R17), N(R16)CO(R17), N(R16)SO 2 (R17), CO(R16), (CR16R17) 0 -O(R18), O—CO—N(R16)(R17), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R16)(R17), wherein the phenyl or heteroaryl may in turn be substituted one or more times by

F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy—(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R19)(R20), SO 2 —CH 3 , SF 5 , COOH, COO—(C 1 -C 6 ) -alkyl, CON(R19)(R20), N(R19)CO(R20), N(R19)SO 2 (R20), CO(R19), (CR19R20) 0 ′—O(R21), O—CO—N(R19)(R20), O—CO—(C 1 -C 6 ) -alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, or O—CO—(C 1 -C 6 )-alkylene-CO—N(R19)(R20); or

R1, R1a and R1b may independently be a radical of formula Ib

or a tautomeric form or a physiologically tolerated salt thereof.

4. The compound according to claim 1 , wherein:

Y is —(C═O)—; and

X is —C(R3)(R4)-; or

X is —(C═O)—; and

Y is —C(R3(R4)-;

R is (CR5R6) m -O(R7), phenyl, or —CH 2 -phenyl, wherein the phenyl may be substituted once or twice by F, Cl, Br, CF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, O—(C 2 -C 4 )-haloalkyl, N(R5)(R6), SO 2 —CH 3 , SO 2 —NH 2 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R5)(R6), CO(R5), or (CR5R6) ) m ′—O(R7); or

R and X when X is —C(R3)(R4)-, together with the nitrogen atom to which they are attached form a monocyclic, saturated 6-membered ring system or a bicyclic partly unsaturated 9- to 11-membered ring system whose individual members may be replaced by one to two atoms or atomic groups selected from —CHR11-, —CR11R12-, —(C═R11)-, and =C(R11)-;

m and m′ are independently 0, 1, 2, or 3;

R11 and R12 are independently hydrogen or (C 1 -C 6 )-alkyl;

R1 is (C 5 -C 8 )-alkyl, —CH 2 -phenyl, or (C 1 -C 2 )-alkylene-heteroaryl, —CH 2 —(C 5 -C 7 )-cycloalkyl, or (C 5 -C 6 )-cycloalkyl, wherein the heteroaryl is thiophene, benzothiophene, pyridine, or pyrazole, and wherein the phenyl, heteroaryl or cycloalkyl may be substituted one or more times by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 ) -alkyl, (C 1 -C 6 )-alkyl, (C 0 -C 8 )-alkylene-phenyl, O—(C 0 -C 8 )-alkylene-phenyl, (C 0 -C 8 )-alkylene-heteroaryl, N(R16)(R17), SO 2 —CH 3 , SO 2 —NH 2 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R16)(R17), CO(R16), or (CR16R17) o -O(R18), wherein the phenyl or heteroaryl may in turn be substituted one or more times by

F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, COOH, CCO—(C 1 -C 6 )-alkyl, CON(R19)(R20), CO(R19), or (CR19R20) 0 -O(R21);

o and o′ are independently 0, 1, 2, and 3;

R1 is a radical selected from the group consisting of

R22, R23, R28, R29, R28a and R29a are independently hydrogen or (C 1 -C 6 )-alkyl,

R2 is hydrogen; and

R3 and R4 are independently hydrogen or methyl;

or a tautomeric form or a physiologically tolerated salt thereof.

5. The compound according to claim 4 , wherein:

R22, R23, R28, R29, R28a and R29a are independently hydrogen or methyl;

or a tautomeric form or a physiologically tolerated salt thereof.

6. The compound according to claim 1 , wherein:

Y is —(C═O)—; and

X is —C(R3)(R4)-; or

X is —(C═O)—; and

Y is —C(R3(R4)-;

R is (CR5R6) m -O(R7), or —CH 2 -phenyl, wherein the phenyl may be substituted once or twice by F, Cl, Br, CF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 ) -alkyl, O—(C 2 -C 4 )-haloalkyl, COOH, CCO—(C 1 -C 6 )-alkyl, CON(R5)(R6), CO(R5), or (CR5R6) m ′—O(R7); or

R and X when X is —C(R3)(R4)-, together with the nitrogen atom to which they are attached form a monocyclic, saturated 6-membered ring system to which a benzene nucleus may be fused, whose individual members of the ring systems may be replaced by one to two atomic groups selected from —CHR11-, —CR11R12-, —(C═R11)-, and =C(R11)-;

m and m′ are independently 0, 1, 2, or 3;

R5, R6 and R7 are independently hydrogen or (C 1 -C 4 )-alkyl;

R11 and R12 are independently hydrogen or (C 1 -CO-alkyl;

R1 is (C 5 -C 8 )-alkyl, —CH 2 -phenyl, (C 1 -C 2 )-alkylene-heteroaryl, —CH 2 -cyclohexyl, or cyclohexyl, wherein the heteroaryl is thiophene or benzothiophene, and wherein the phenyl, heteroaryl or cyclohexyl may be substituted once or twice by F, Cl, OH, CF 3 , OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 0 -C 1 )-alkylene-phenyl, O—phenyl, (C 0 -C 1 )-alkylene-heteroaryl, N(R16)(R17), COOH, COO—(C 1 -C 6 )-alkyl, CON(R16)(R17), CO(R16), or (CR16R17) 0 -O(R18), wherein the phenyl or heteroaryl may in turn be substituted once or twice by

F, Cl, OH, CF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, COOH, COO—(C 1 -C 6 ) -alkyl, CON(R19)(R20), CO(R19), or (CR19R20) 0 -O(R21);

o and o′ are 0, 1, 2 or 3; or

R1 is a radical selected from the group consisting of

R22, R23, R28, R29, R28a and R29a are independently hydrogen or (C 1 -C 6 )-alkyl;

R2 is hydrogen; and

R3 and R4 are independently hydrogen or methyl;

or a tautomeric form or a physiologically tolerated salt thereof.

7. The compound according to claim 6 , wherein:

R22, R23, R28, R29, R28a and R29a are independently hydrogen or methyl;

or a tautomeric form or a physiologically tolerated salt thereof

8. The compound according to claim 1 , wherein:

Y is —(C═O)—; and

X is —C(R3)(R4)-; or

X is —(C═O)—; and

Y is —C(R3)(R4)-;

R is HO—CH 2 —, or benzyl, or

R and X when X is —C(—R3)(R4)-, together form —CH 2 —CH 2 —CH 2 —CH 2 - or

R1 is pentyl, hexyl, heptyl, cyclohexyl, —CH 2 -cyclohexyl, —CH 2 -phenyl, —CH 2 -thiophene, or —CH 2 —CH 2 -thiophene, wherein the cyclohexyl, phenyl or thiophene may be substituted by methyl; or

R1 is a radical selected from the group consisting of

R22, R23, R28, R29, R28a, and R29a are hydrogen;

R2 is hydrogen; and

R3 andR4 are independently hydrogen or methyl;

or a tautomeric form or a physiologically tolerated salt thereof.

9. The compound according to claim 1 , which is:

3-Benzyl-2,5-dioxoimidazolidine-1-hexylcarboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-(2-methylbenzyl)carboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1((S)- indan-1-Acarboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-((R)-indan-1-yl)carboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-(1,2,3,4-tetrahydronaphthalen--yl)carboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-(2-thiophen-2-ylethyl)carboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-heptylcarboxamide;

3-Benzyl-2,4-dioxoimidazolidine-1-hexylcarboxamide;

3-Benzyl-2,4-dioxoimidazolidine-1-(2-methylbenzyl)carboxamide;

3-Benzyl-2,4-dioxoimidazolidine-1-heptylcarboxamide;

3-Benzyl-2,4-dioxoimidazolidine-1-(2-thiophen-2-ylethyl)carboxamide;

3-(5,5-Dimethyl-2-oxotetrahydrofuran-3-yl)-5,5-dimethyl-2,4-dioxoimidazolidine-l-hexylcarboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-pentylcarboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-cyclohexylcarboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-cyclohexylmethylcarboxamide;

3-Benzyl-2,5-dioxoimidazolidine-1-benzylcarboxamide;

1,3-Dioxohexahydroimidazo[1,5-a]pyridine-2-hexylcarboxamide;

1,3-Dioxo-1,5,10,10a-tetrahydroimidazo[1,5-]isoquinoline-2-hexylcarboxamide;

1,3-Dioxohexahydroimidazo[1,5-a]pyridine-2-(2-methylbenzyl)carboxamide;

1,3-Dioxo-1,5,10,10a-tetrahydroimidazo[1,5-]isoquinoline-24(S)—indan-1-yl)carboxamide;

1,3-Dioxo-1,5,10,10a-tetrahydroimidazo[1,5-]isoquinoline-24(R)-indan-1-yl)carboxamide;

1,3-Dioxo-1,5,10,10a-tetrahydroimidazo[1,5-]isoquinoline-2-(1,2,3,4-tetrahydronaphthalen-1- y1)carboxamide;

1,3-Dioxo-1,5,10,10a-tetrahydroimidazo[1,5-b ]isoquinoline-2-methylbenzyl-2-carboxamide;

1,3-Dioxohexahydroimidazo[1,5-a]pyridine-24(S)—1,2,3,4-tetrahydronaphthalen-1- yl)carboxamide;

1,3-Dioxohexahydroimidazo[1,5-a]pyridine-24(S)—indan-1-yl)carboxamide; or

1,3-Dioxohexahydroimidazo[1,5-a]pyridine-24(R)-indan-1-yl)carboxamide;

or a tautomeric form or a physiologically tolerated salt thereof.

10. A pharmaceutical composition comprising the compound according to claim 1 , or a tautomeric form or a physiologically tolerated salt thereof, in combination with a pharmacologically acceptable carrier or excipient.

11. A pharmaceutical composition comprising the compound according to claim 9 , or a tautomeric form or a physiologically tolerated salt thereof, in combination with a pharmacologically acceptable carrier or excipient.

12. The pharmaceutical composition according to claim 10 , further comprising an active ingredient selected from the group consisting of antidiabetics, hypoglycemic active ingredients, FIMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, a-glucosidase inhibitors, active ingredients acting on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin antagonists, H3 agonists, TNF agonists, CRF antagonists, CRF BP antagonists, urocortin agonists, β3 agonists, melanocyte-stimulating hormone agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists, lipase/amylase inhibitors, PPAR modulators, RXR modulators, TR-βagonists and amphetamines.